The Department of Hematology and Oncology at the University Hospital Frankfurt provides a comprehensive range of diagnostic and therapeutic services for patients with solid tumors and malignancies of the hematopoietic system. Within this scientific environment, the research group led by Prof. Dr. med. Thomas Oellerich focuses on uncovering oncogenic signaling pathways, regulators of tumor viability, and mechanisms of resistance to therapies, with a primary emphasis on acute myeloid leukemia (AML) and aggressive lymphomas.
The Oellerich Lab leverages cutting-edge proteogenomics and functional genomics to explore the molecular underpinnings of hematological cancers. The laboratory is part of the Frankfurt Cancer Institute (FCI) and the German Consortium for Translational Cancer Research (DKTK), supported by the research infrastructure of the University Hospital Frankfurt and the Georg-Speyer-Haus. Strategic collaborations with international institutions, including the NIH and the Dana-Farber Cancer Center, further enhance the lab's global impact.
Single-cell CRISPR/Cas9 screening technologies
Universitätsklinikum Frankfurt